Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1601-1611

  Ganapathy, Manonmani ^a   Ghosh, Rita ^a   Jianping, Xie ^a   Zhang, Xiaoping ^c   Bedolla, Roble ^b   Schoolfield, John ^b   Yeh, I Tien ^b   Troyer, Dean A ^b   Olumi, Aria F ^c   Kumar, Addanki P ^a  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANDROGEN; CASPASE 8; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BID; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TRANSIENT TRANSFECTION; TREATMENT RESPONSE;

ADENOCARCINOMA; ANIMALS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; ESTRADIOL; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANSFECTION; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 63449135315     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1389     Document Type: Article

References (49)

1. Broker LE, Kruyt FAE, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005;11:3155-62.
2. Nicholson DW. From bench to clinic with apoptosisbased therapeutic agents. Insight Review articles. Nature 2000;407:810-6.
3. Nagata S. Golstein P. The Fas death factor. Science 1995;267:1449-56.
4. Krueger A, Baumann S, Krammer PH, et al. FLICE- inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247-54.
5. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388: 190-5.
6. Golks A, Brenner D, Fritsch C, et al. C-FLIPR: a new regulator of death receptor-induced apoptosis. J Biol Chem 2005;280:14507-13.
7. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
8. Rippo MR, Moretti S, Vescovi S, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004;23: 7753-60.
9. Mathas S, Lietz A, Anagnostopoulos I, et al. C-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041 -52.
10. Guseva NV, Rokhlin OW, Taghivev AF, et al. Unique resistance of breast carcinoma cell lineT47D to TRAIL but not anti-Fas is linked to p43cFLIP (L). Breast Cancer ResTreat 2008;107:349-57.
11. Rogers KMA, Thomas M, Galligan L, et al. Cellular FLICE-inhibitory protein regulates chemotherapy- induced apoptosis in breast cancer cells. Mol Cancer Ther 2007;6:1544-51.
12. Ullenhag GJ, Mukherjee A, Watson NF, et al. Overexpression of FLIPl is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007;13:5070-5.
13. Korkolopoulou P, Saetta AA, Levidou G, et al. c- FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathol 2007;51:150-6.
14. Bullani RR, Huard B, Viard-Leveugle I, et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 2001;117:360-4.
15. Thomas RK, Kallenborn A, Wickenhauser C, et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 2002;160: 1521 -8.
16. Benesch M, Platzbecker U, Ward J, et al. Expression of FLIP (long) and FLIP (short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 2003;17:2460-6.
17. Korkolopoulou P, Goudopoulou A, Voutsinas G, et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004;64: 1198-04.
18. Lee SH, Kim HS, Kim SY, et al. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS 2003;111:309-14.
19. Gao S, Lee P, Wang H, et al.The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005;19:1792-802.
20. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL- resistant prostate cancer cells by activating c-Fos/ c-Jun heterodimers and repressing c-FLIP (L). Cancer Res 2007;67:2247-55.
21. Benoit V, Chariot A, Delacroix L, et al. Caspase-8- dependent HER-2 cleavage in response to tumor necrosis factor α stimulation is counteracted by nuclear factor-κB through c-FLIP-L expression. Cancer Res 2004;64:2684-91.
22. Okamoto K, Fujisawa J-I, Reth M, et al. Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-κB. Genes Cells 2006;11: 177-91.
23. Ricci MS, Jin Z, Dews M, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541 -55.
24. Fukazawa T, Fujiwara T, Uno F, et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteosome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 2001;20: 5225-31.
25. Shurk C, Maatz H, Kim HS, et al. The Akt-regulated Forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004;279: 1513-25.
26. Chang I, Kamata H, Solinas G, et al.The E3 ubiquitin ligase Itch couples JNK activation toTNFα-induced cell death by inducing c-FLIPL turnover. Cell 2006; 124:601 -13.
27. Hyer ML, Croxton R, Krajewska M, et al. Synthetic triterpenoids cooperate with tumor necrosis factorrelated apoptosisinducing ligand to induce apoptosis of breast cancer cells. Cancer Res 2005;65:4799-808.
28. Palacios C, Yerbes R, Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteosome and promotesTRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006;66:8858-69.
29. Son Y-G, Kim E-H, Kim JY, et al. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP andsurvivin. CancerRes2007;67:8274-84.
30. Yang, JK. FLIP as an anti-cancer therapeutic target. YonseiMedJ2008;49: 19-27.
31. Sutherland TE, Anderson RL, Hughes RA, et al. 2-Methoxyestradiol-a unique blend of activities generating a new class of anti-tumor/anti-inflammatory agents. Drug Discov Today 2007;12:577-84.
32. 2/M phase and inhibits growth of human prostate cancer cells. Mol Carcinogen 2001;31:111 -24.
33. Garcia GE, Wisniewski H, Lucia MS, et al. 2- Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-α-stimulated gene 6. Clin Cancer Res 2006;12:980-8.
34. Bhati R, Gökmen-Polar Y, Sledge GW, Jr., et al. 2- Methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells. Cancer Res 2007;67:702-8.
35. 2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction andapoptosis. Carcinogenesis2003;24:1067-75.
36. Sweeney C, Liu G, Yiannoutsos C, et al. AphaseII multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;15:6625-33.
37. Shimada K, Nakamura M, Ishida E, et al.Themolecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells. Mol Carcinog 2004;39:1 -9.
38. Pearse I, Zhu Y X, Murray EJ, et al. Sp1and Sp3 control constitutive expression of the human NHE2 promoter by interactions with the proximal promoter and the transcription initiation site. Biochem J 2007;407: 101 -11.
39. Kumar AP, Butler AP. Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 1999;137:159-65.
40. Chintharlapalli S, Papineni S, Ramaiah SK, et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007;67:2816-23.
41. Kanai M, Wei D, Li Q, et al.Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res 2006;12:6395-402.
42. 2-kinase and Sp1/Sp3. Cancer Res 2006;66:1363-70.
43. Kumar AP, Butler AP. Transcription factor Sp3 antagonizes activation of the ornithine decarboxylase promoter by Sp1. Nucleic Acids Res 1997;25:2012-9.
44. R. Neoplasia 2007;9:893-9.
45. Kumar AP, Bhaskaran S, Ganapathy M, et al. Akt/CREB/Cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate (TRAMP) model mediated by Nexrutine®, a Phellodendron amurense bark extract. Clin Cancer Res 2007;13:2784-94.
46. Matys V, Fricke E, Geffers R, et al. Transfac: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003;31:374-8.
47. Ishibashi H, Nakagawa K, Onimaru M, et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000;60:6531 -6.
48. Lou Z, O'Reilly S, Liang H, et al. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005;65: 1007-17.
49. Gao S, Wang H, Lee P, et al. Androgen receptor and prostateapoptosis response factor-4 target the c-FLIP geneto determine survival and apoptosis in theprostate gland. J Mol Endocrinol 2006;36:463-83.